JP2018184428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018184428A5 JP2018184428A5 JP2018131226A JP2018131226A JP2018184428A5 JP 2018184428 A5 JP2018184428 A5 JP 2018184428A5 JP 2018131226 A JP2018131226 A JP 2018131226A JP 2018131226 A JP2018131226 A JP 2018131226A JP 2018184428 A5 JP2018184428 A5 JP 2018184428A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf11
- activity
- level
- seq
- configuration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718126P | 2012-10-24 | 2012-10-24 | |
| US61/718,126 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Division JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020108569A Division JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018184428A JP2018184428A (ja) | 2018-11-22 |
| JP2018184428A5 true JP2018184428A5 (enExample) | 2019-01-10 |
Family
ID=50545462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150276766A1 (enExample) |
| EP (2) | EP3608419B1 (enExample) |
| JP (3) | JP6401171B2 (enExample) |
| CN (2) | CN104968801B (enExample) |
| AU (3) | AU2013334659B2 (enExample) |
| CA (1) | CA2889209C (enExample) |
| ES (2) | ES2753811T3 (enExample) |
| IL (3) | IL290653B2 (enExample) |
| SA (1) | SA515360337B1 (enExample) |
| WO (1) | WO2014066486A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| MX388380B (es) * | 2014-04-18 | 2025-03-19 | Acceleron Pharma Inc | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| AU2015353767B2 (en) * | 2014-11-24 | 2021-09-09 | Somalogic Operating Co., Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
| DK3227675T3 (da) * | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| WO2016183280A1 (en) * | 2015-05-13 | 2016-11-17 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108350057A (zh) * | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| EP3370754A4 (en) * | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CN105738614B (zh) * | 2016-02-23 | 2017-12-05 | 山东大学 | 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法 |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| KR20230010641A (ko) | 2020-05-15 | 2023-01-19 | 셀진 코포레이션 | ACTRIIB 리간드 트랩 및 mTOR 억제제를 사용한 빈혈 치료 방법 및 조성물 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DK0776337T3 (da) * | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101871510B1 (ko) * | 2008-06-26 | 2018-06-26 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EA027071B1 (ru) * | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| CA2770822C (en) | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| WO2012064771A1 (en) * | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
-
2013
- 2013-10-23 CA CA2889209A patent/CA2889209C/en active Active
- 2013-10-23 JP JP2015539750A patent/JP6401171B2/ja active Active
- 2013-10-23 CN CN201380067792.8A patent/CN104968801B/zh active Active
- 2013-10-23 IL IL290653A patent/IL290653B2/en unknown
- 2013-10-23 AU AU2013334659A patent/AU2013334659B2/en active Active
- 2013-10-23 WO PCT/US2013/066350 patent/WO2014066486A2/en not_active Ceased
- 2013-10-23 EP EP19184182.4A patent/EP3608419B1/en active Active
- 2013-10-23 CN CN202110622231.6A patent/CN113604550A/zh active Pending
- 2013-10-23 US US14/438,120 patent/US20150276766A1/en not_active Abandoned
- 2013-10-23 ES ES13848471T patent/ES2753811T3/es active Active
- 2013-10-23 ES ES19184182T patent/ES3031001T3/es active Active
- 2013-10-23 IL IL267663A patent/IL267663B/en unknown
- 2013-10-23 EP EP13848471.2A patent/EP2912462B1/en active Active
-
2015
- 2015-04-21 IL IL238414A patent/IL238414B/en active IP Right Grant
- 2015-04-23 SA SA515360337A patent/SA515360337B1/ar unknown
-
2018
- 2018-03-09 US US15/916,634 patent/US20190049469A1/en not_active Abandoned
- 2018-07-11 JP JP2018131226A patent/JP2018184428A/ja active Pending
-
2019
- 2019-06-12 AU AU2019204098A patent/AU2019204098B2/en active Active
-
2020
- 2020-06-24 JP JP2020108569A patent/JP7146850B2/ja active Active
-
2021
- 2021-09-21 AU AU2021236465A patent/AU2021236465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018184428A5 (enExample) | ||
| JP2016500698A5 (enExample) | ||
| JP2020183389A5 (enExample) | ||
| Hyldgaard et al. | A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality | |
| Hartings et al. | Spreading depolarizations have prolonged direct current shifts and are associated with poor outcome in brain trauma | |
| Macrez et al. | Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities | |
| Pöpplau et al. | Reorganization of adolescent prefrontal cortex circuitry is required for mouse cognitive maturation | |
| Iglesias‐Linares et al. | The use of gene therapy vs. corticotomy surgery in accelerating orthodontic tooth movement | |
| Hazebroek et al. | Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial | |
| UA126786C2 (uk) | Fgfr/pd-1 комплексна терапія для лікування раку | |
| JP2018522579A5 (enExample) | ||
| KR20180002838A (ko) | 모발 생장을 촉진하기 위한 방법 및 조성물 | |
| Piątkiewicz et al. | The dysfunction of NK cells in patients with type 2 diabetes and colon cancer | |
| Gossec et al. | Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis | |
| Stasyshyn et al. | Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study | |
| EP4371125A1 (en) | Multi-variate model for predicting cytokine release syndrome | |
| Ganesan et al. | Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape | |
| Jiang et al. | Anti-CCL21 antibody attenuates infarct size and improves cardiac remodeling after myocardial infarction | |
| Vega Memije et al. | Actinic prurigo as a hypersensitivity reaction type 4 | |
| Theilen et al. | TFAM overexpression diminishes skeletal muscle atrophy after hindlimb suspension in mice | |
| Xie et al. | Direct and indirect costs of osteoarthritis in Singapore: a comparative study among multiethnic Asian patients with osteoarthritis. | |
| JP5296530B2 (ja) | 移植片対宿主病予知マーカーおよびその利用 | |
| Ge et al. | Metabolic reprogramming through histone lactylation in microglia and macrophages recruits CD8+ T lymphocytes and aggravates spinal cord injury | |
| Wang et al. | The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial | |
| Asai et al. | Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study |